PMID- 35789988
OWN - NLM
STAT- MEDLINE
DCOM- 20220829
LR  - 20220830
IS  - 1179-2000 (Electronic)
IS  - 1177-1062 (Linking)
VI  - 26
IP  - 5
DP  - 2022 Sep
TI  - Associations between HLA-Cw1 and Systemic Treatment Response of Asian Psoriasis 
      Patients.
PG  - 541-549
LID - 10.1007/s40291-022-00603-4 [doi]
AB  - INTRODUCTION: Psoriasis is a chronic inflammatory disease with a strong genetic 
      background, particularly the human leukocyte antigen (HLA). HLA-Cw6 has been 
      shown to be the major disease susceptibility locus and affects the phenotypes and 
      treatment response in psoriasis; however, the prevalence of HLA-Cw6 is far lower 
      than HLA-Cw1 in some Asian countries. OBJECTIVES: The aim of this study was to 
      determine whether HLA-Cw1 predisposes psoriasis patients to different treatment 
      responses of biologics and other systemic therapy. METHODS: This retrospective 
      case-control study included 126 patients with moderate to severe plaque-type 
      psoriasis who had been genotyped and treated in a special psoriasis clinic. 
      HLA-Cw1-positive and -negative patients were compared. RESULTS: Our results 
      showed that HLA-Cw1-negative patients were significantly more likely to respond 
      (achieve Psoriasis Area and Severity Index [PASI] 75 after a 12- to 16-week 
      treatment course) to biologics (including etanercept, adalimumab, ustekinumab, 
      secukinumab, ixekizumab, and guselkumab; odds ratio [OR] 1.99, 95% confidence 
      interval [CI] 1.17-3.44, p = 0.0122) and especially to ustekinumab (OR 3.27, 95% 
      CI 1.03-11.30; p = 0.0496). An HLA-Cw1 allele dose effect was also found. The 
      results remained after multivariate logistic regression analysis. 
      HLA-Cw1-negative patients also showed significantly greater improvement of PASI 
      in ustekinumab and biologics (p = 0.0044 and p = 0.0064, respectively), with 
      other biologics showing non-significant trends. HLA-Cw1 status did not affect the 
      treatment responses of non-biologic systemic treatment, including phototherapy. 
      CONCLUSION: There is an association between HLA-Cw1 and treatment response to 
      biologics, but not to non-biologics, in our Asian population of patients with 
      moderate to severe psoriasis; however, the exact mechanism and role of HLA-Cw1 
      remain to be investigated.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
FAU - Ho, Shin-Shin
AU  - Ho SS
AUID- ORCID: 0000-0001-9974-8614
AD  - National Taiwan University Hospital, No. 7 Chung San South Road, Taipei, Taiwan.
FAU - Tsai, Tsen-Fang
AU  - Tsai TF
AUID- ORCID: 0000-0002-1498-1474
AD  - National Taiwan University Hospital, No. 7 Chung San South Road, Taipei, Taiwan. 
      tftsai@yahoo.com.
AD  - Department of Dermatology, National Taiwan University Hospital and National 
      Taiwan University College of Medicine, Taipei, Taiwan. tftsai@yahoo.com.
LA  - eng
PT  - Journal Article
DEP - 20220705
PL  - New Zealand
TA  - Mol Diagn Ther
JT  - Molecular diagnosis & therapy
JID - 101264260
RN  - 0 (HLA-C Antigens)
RN  - 0 (HLA-Cw1 antigen)
RN  - FU77B4U5Z0 (Ustekinumab)
SB  - IM
MH  - Case-Control Studies
MH  - HLA-C Antigens
MH  - Humans
MH  - *Psoriasis/drug therapy/genetics
MH  - Retrospective Studies
MH  - Severity of Illness Index
MH  - Treatment Outcome
MH  - *Ustekinumab/therapeutic use
EDAT- 2022/07/06 06:00
MHDA- 2022/08/30 06:00
CRDT- 2022/07/05 20:06
PHST- 2022/06/06 00:00 [accepted]
PHST- 2022/07/06 06:00 [pubmed]
PHST- 2022/08/30 06:00 [medline]
PHST- 2022/07/05 20:06 [entrez]
AID - 10.1007/s40291-022-00603-4 [pii]
AID - 10.1007/s40291-022-00603-4 [doi]
PST - ppublish
SO  - Mol Diagn Ther. 2022 Sep;26(5):541-549. doi: 10.1007/s40291-022-00603-4. Epub 
      2022 Jul 5.